A Phase 2A Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of 50 MG and 100 MG Of SUVN-502 In Subjects With Moderate Alzheimer's Disease Currently Treated with Donepezil Hydrochloride and Memantine Hydrochloride

Grants and Contracts Details

StatusFinished
Effective start/end date3/2/17 → 1/22/20

Funding

  • Parexel International Co: $132,961.00